Superpower Launches Peptides, Connecting Prescription Peptide Care With Comprehensive Blood Testing

Members can now access clinician-guided peptide protocols—beginning with BPC-157, TB-500, and MOTS-C—brought together with Superpower's blood testing and ongoing clinical support in one experience.

SAN FRANCISCO, Nov. 2, 2026 /PRNewswire/ -- Superpower, the human health company on a mission to enhance and extend human life, announces the launch of Superpower Peptides. Members can now sign up for pre-orders for prescribed peptide treatments, following clinical consults. The introduction of curated and clinically monitored peptides complements Superpower's existing platform, which integrates extensive blood testing with wearable data; uses powerful AI to identify personalized insights, actions plans, and supplements; and connects patients with licensed clinicians for prescription medication consultations.

The announcement follows the recent interim policy released by the Department of Health and Human Services (HHS). HHS acknowledged the significant interest in peptides and stated that it does not intend to take enforcement action against licensed pharmacies and physicians that compound these peptides under specified safeguards. HHS expressed its intent to facilitate patient access and provide a more controlled alternative to unregulated "research use only" products while the FDA completes formal rule making.

Superpower has been preparing for this moment: carefully building a supply chain with trusted pharmacy partners, developing clinical protocols, and integrating peptide care with its blood testing so that clinicians can understand a member's baseline and monitor their health throughout treatment.

Peptides have become one of the most talked-about frontiers in health, but access has often outpaced guidance. Superpower Peptides is built to change that, pairing treatment with the context that makes it meaningful: a clear picture of health history, goals, and baseline bloodwork, reviewed with a licensed clinician.

"We're not iterating on healthcare, we're rebuilding it," said Max Marchione, CEO of Superpower. "Understanding your body and deciding how to care for it should be connected, so we're bringing clinical expertise, cutting edge research, and powerful AI together to build better healthcare at a bigger scale. Superpower is redefining the relationship between you, your health data, and your care team. Now, peptides are part of that system."

A Connected Approach to Peptide Care

Clinical evaluation, regular check-ins, and lab monitoring are built into the approach, so care is informed by a member's own data rather than guesswork. Together with trusted clinicians like Dr. Sara Szal, Dr. Alex Tatem, and more, the company is bringing these pieces into one experience. From evaluation through ongoing care, Superpower is shaping how the healthcare industry develops protocols, explains the evidence, and supports people through treatment.

The launch lineup features single-compound peptides including BPC-157, TB-500, and MOTS-C that will be available to members through clinical intake. As Superpower expands the program, it intends to be clear about what's available, what the evidence supports, and what is still being learned.

Built on Quality & Assurance Standards

Every Superpower Peptides offering is designed around a consistent set of quality and assurance standards:

• Treatment only available if prescribed by licensed providers
• Clinically guided protocols
• Comprehensive blood testing and monitoring
• Prescriptions filled by U.S.-licensed pharmacies
• Active ingredients from FDA-registered facilities
• Batch-level third-party testing
• Produced in the USA

Availability

Superpower Peptides is available for pre-order now, with shipping coming at the end of November 2026. To learn more or get first access, visit superpower.com/peptides.

We've been preparing for this moment. Now, we're ready to bring it to you. Welcome to the world of Superpower.

About Superpower

Superpower is a preventive health company on a mission to build a new healthcare system. Through comprehensive blood testing, members get a detailed baseline across 100+ biomarkers, then connect those insights to personalized guidance and care. With the launch of Superpower Peptides, the company extends that experience from evaluation through ongoing, clinician-supported treatment.

Peptides offered through Superpower are compounded medications that have not been approved or authorized by the FDA. They are made available under an interim HHS enforcement discretion policy that may be revised or rescinded at any time, and they may not be available in all states. Evidence on their safety and effectiveness in humans is limited, and they are not appropriate for everyone. Treatment is available only if prescribed by a licensed clinician following an individual evaluation.

SOURCE Superpower